TORONTO--(BUSINESS WIRE)--

Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) is pleased to provide an update on it second pipeline drug, ATB-352, a potent pain-killer intended for the relief of acute, severe pain. Recently completed pre-clinical studies have now demonstrated that ATB-352, unlike opiate drugs, does not bind to opioid receptors and therefore does not pose a risk of addiction.

Opiates, such as oxycontin and fentanyl, are among the most widely used drugs to relieve acute, severe pain, with annual sales exceeding US$7 billion. However, these drugs carry a high risk of addiction and abuse. As earlier announced, Antibe is developing ATB-352, a novel hydrogen sulfide-releasing analgesic, to address the growing need for a powerful but safe and non-addictive pain-killer.

ATB-352 reduces pain by very potently suppressing production of pain-signaling substances called “prostaglandins”. The drug is rapidly absorbed and shows a pharmacokinetic profile consistent with once-daily dosing. ATB-352 is a derivative of ketoprofen, a powerful analgesic that carries a high risk of producing gastrointestinal ulcers. However, in animal studies, ATB-352 did not cause ulcers or bleeding, even when given at high doses daily for 5 days. Small amounts of hydrogen sulfide released from ATB-352 protect the lining of the GI tract, and provide additional analgesic and anti-inflammatory effects.

John Wallace, Antibe’s Chief Scientific Officer, remarked, “ATB-352 is intended for short-term use in relieving severe pain, such as that associated with migraine, toothache, sports injuries, post-surgery, dysmenorrhea, and a variety of other conditions. Because of the intended short-term use, the development plan for ATB-352 is considerably accelerated as compared to that for a chronic-use drug, such as ATB-346, Antibe’s lead drug being developed for the treatment of arthritis.”

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.

Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.

Forward Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its ability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005391/en/